3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Sarcoma
1
Neoplasms
1
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
Cyclophosphamide
19
fludarabine
18
Tacrolimus
10
Whole-Body Irradiation
9
Mycophenolic Acid
8
venetoclax
7
fludarabine phosphate
7
Sirolimus
7
Azacitidine
7
Mesna
5
Dexamethasone
5
Bortezomib
5
Rituximab
4
Methotrexate
4
Busulfan
4
daratumumab
3
Stem Cell Transplantation
3
Peripheral Blood Stem Cell Transplantation
3
Nivolumab
3
Melphalan
3
Lenalidomide
3
Filgrastim
3
Cytarabine
3
Biopsy
3
Alemtuzumab
3
AP 1903 reagent
3
pomalidomide
2
merphos
2
isatuximab
2
ibrutinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Hematologic Neoplasms
×
bexmarilimab
×
Clear all
NCT05428969
2026-04-23
BEXMAB
Faron Pharmaceuticals Ltd
Phase 1/2
Active not recruiting
181 enrolled